NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 20 January 2022 at 09:30am

**Location:** via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Ms Anna Pracz Present for all items
4. Mr Gabriel Rogers Present for all items
5. Professor Iolo Doull Present for all items
6. Dr James Fotheringham Present for all items
7. Dr Laura Bojke Present for all items
8. Ms Maria Bretzitski Present for all items
9. Dr Nicholas Latimer Present for all items
10. Professor Nicky Welton Present for all items
11. Mr Nigel Westwood Present for all items
12. Dr Stephen Smith Present for all items
13. Dr Stuart Williams Present for items 1 to 3.2.2
14. Dr Toby Smith Present for all items
15. Mr Tony Wootton Present for all items
16. Dr Veline L’Esperance Present for all items

NICE staff present

Richard Diaz, Associate Director Present for items 4 to 4.3.

Henry Edwards, Associate Director Present for all items 1 to 3.2.2

Daniel Davies, Project Manager Present for items 4 to 4.3.1

Shonagh D’Sylva, Project Manager Present for item 1 to 3.2.2

Yelan Guo, HTA Advisor Present for items 4 to 4.3.1

Catherine Spanswick, HTA Analyst Present for items 1 to 3.2.2

Jeremy Dietz, Technical Analyst Present for items 1 to 3.2.2

Michelle Green, Technical Advisor Present for items 1 to 3.2.2

Emily Eaton Turner, Technical Advisor Present for items 4 to 4.3.1

Korin Knight, Senior Medical Editor Present for items 1 to 3.2.2

Emeline Coventry, Senior Medical Editor Present for items 4 to 4.3.2

Rosalee Mason, Coordinator, MiP Present for all items 1 to 4.3

Emma Gordon, Administrator, TA Present for items 4 to 4.3.1

Laura Marsden, Public Involvement Advisor Present for items 1 to 3.2.2

Ella Fitzpatrick, Public Involvement Advisor Present for items 1 to 3.2.2

Laura Kelly, Administrator, COT Present for all items

Rumana Zaman, Administrator, Technical Team Present for all items

Evidence review group representatives present

Vicky Wakefield, BMJ Group Present for items 1 to 3.1.3

Mariana Bacelar, BMJ Group Present for items 1 to 3.1.3

Ben Wijnen, Kleijnen Systematic Reviews Present for items 4 to 4.2.1

Bram Ramaekers, Kleijnen Systematic Reviews Present for items 4 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Present for items 4 to 4.2.1

Experts present

Dr Matthew Streetly, Clinical Expert Present for items 1 to 3.1.3

Ms Shelagh McKinlay, Patient Expert Present for items 1 to 3.1.3

Mr David Anthony Lobb, Patient Expert Present for items 1 to 3.1.3

Dr Peter Clark, Clinical Expert Present for items 1 to 3.1.3

Professor Helen Cross, Clinical Expert Present for items 4 to 4.1.3

Ms Claire Eldred, Patient Expert Present for items 4 to 4.1.3

Mrs Galia Wilson-John, Patient Expert Present for items 4 to 4.1.3

Observers present

Lynne Kincaid, Senior Analyst, NICE Present for items 4 to 4.3.1

Lizzie Walker, HTA Analyst, NICE Present for items 4 to 4.3.1

Philip Williams, Finance/Business Analyst, NICE Present for all items

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted in advance for apologies from Denise Bryceland and Peter Wheatley Price. Apologies from Rhiannon Owen and Mary Weatherstone were noted on the day.

### News and announcements

* 1. None.

### Appraisal of Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (CDF review of TA510) [ID3881]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen-Cilag Ltd.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Peter Wheatley-Price declared a direct financial interest prior to the meeting. His employer, Takeda, manufacture Ixazomib used in combination dexamethasone and lenalidomide in this exact indication. Ixazomib is currently also on CDF. It was agreed that this declaration would prevent Mr Peter Wheatley-Price from participating in this discussion.
* Dr Matthew Streetly declared a direct financial interest as he has participated on the advisory board for Celgene, Takeda, Janssen-Cilag. It was agreed this declaration would not prevent Dr Matthew Streetly from participating in this discussion.
* Ms Shelagh McKinlay declared an indirect financial interest, as Myeloma UK receives grant funding from the submitting company and comparator companies.

Myeloma UK is also paid honoraria from time to time from both the submitting company and comparator companies in recognition of individual members of staff participation in e.g workshops or advisory boards. It was agreed this declaration would not prevent Shelagh McKinlay from participating in this discussion.

* + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Stuart Williams (clinical lead) Henry Edwards (cost lead), and Tony Wootton (lay lead).
  1. Part 2 –Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD.) The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/get-involved/meetings-in-public/technology-appraisal-committee>.

### Appraisal of Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Zogenix International Ltd.
     2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Peter Wheatley-Price declared a direct financial interest: his employer Takeda, completed a deal in March 21 to purchase Soticlestat for the treatment of Dravet and Lennox-Gastaut. The molecule is commencing phase 3 trials now and is due for launch in 2023 or beyond (previously declared at June 2021 committee meeting.) It was agreed that this declaration would prevent Peter Wheatley-Price from participating in this discussion.
* Professor Helen Cross declared a direct non- financial interest as she has sat as chair medical board of Dravet UK, Matthews Friends; Treasurer & President elect International League Against Epilepsy; author of review of fenfluramine in press (information piece, not opinion). Helen also declared an indirect financial interest, having been an investigator in clinical trials for Zogenix, GW Pharma and Marinius, for which remuneration was made to the department. Furthermore, Helen contributed to two symposia (on rare epilepsies and Dravel syndrome) at the British Paediatric Neurology Association meeting in January, sponsored by educational grants from Biocodex and Zogenix. Remuneration was made to the BPMA and department. It was agreed these declarations wouldn’t prevent Professor Helen Cross from participating in this discussion.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Charles Crawley.
  1. Part 2a – Closed session (members of the public, experts and company representatives were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external group representatives were asked to leave the meeting).
     1. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/get-involved/meetings-in-public/technology-appraisal-committee>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 17 February 2022 and will start promptly at 09:30am.